Christian Eberle, president director at APL, explains the challenges and opportunities within the Indonesian healthcare distribution arena as well as the company’s strategy to bring more high-quality medicines to patients over the next two years.
After over two years as CEO of APL, could you provide us with an overview of your key priorities as well as accomplishments?
"Indonesia requires a specific strategy given its scale, as well as its unique challenges and opportunities."
Evie Yulin, biopharma country director at Merck Indonesia, speaks towards the meaning of innovation in emerging countries and how the company engages in innovation beyond products. Since 2012, Merck has been…
Haris Izmee, director at GE Healthcare Indonesia, explains the strong commitment of the company towards improving access, affordability and quality and highlights the company’s significant investments in internal capabilities and…
Marlia Hayati and Joey Romana, President Director and Vice President Director at PT Darya-Varia Laboratoria, share insights about the company’s strong brand equity and pioneering manufacturing strategy. In 2016, the…
With a market value of USD 5.2 billion, Kalbe Farma has consolidated into Indonesia’s undisputed national pharma champion and has established a footprint in many ASEAN countries as well as…
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of…
The latest pharma news from the Asia-Pacific region, including upcoming IPOs for Prestige Biopharma and HH&L Acquisition; logistics challenges for COVID-19 vaccine distributors; and Moderna’s CMO-based vaccine manufacturing strategy in…
See our Cookie Privacy Policy Here